These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 427797)

  • 1. Prognostic factors in metastatic breast cancer treated with combination chemotherapy.
    Swenerton KD; Legha SS; Smith T; Hortobagyi GN; Gehan EA; Yap HY; Gutterman JU; Blumenschein GR
    Cancer Res; 1979 May; 39(5):1552-62. PubMed ID: 427797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
    Chow LW; Day W; Ng KC
    Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
    Manni A; Trujillo JE; Pearson OH
    Cancer Treat Rep; 1980 Jan; 64(1):111-6. PubMed ID: 6155207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estradiol receptor and prognostic parameters of human breast cancer.
    Görlich M; Jandrig B
    Neoplasma; 1999; 46(2):112-6. PubMed ID: 10466435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
    Dalley DN; Levi JA; Aroney RS
    Med J Aust; 1980 Mar; 1(5):216-8. PubMed ID: 6990214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factors in the drug therapy of metastasizing breast cancer].
    Mörz R; Schemper M; Bettelheim P; Breyer S; Francesconi M; Graninger W; Jakesz R; Kolb R; Micksche M; Rainer H; Reiner G; Moser K
    Acta Med Austriaca Suppl; 1979; 6():319-22. PubMed ID: 299219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.